Medicine details

ImageNoanxit
NameNoanxit
DosageTablet
Generic NameFlupenthixol + Melitracen
Classes Central Nervous System Agent
Psychotherapeutic Agent
Antidepressant
Antidepressent Combination
Diseases Anxiety
Apathy
CNS Disorder
Depression
Dysphoria
CompanyReliance Pharmaceuticals Ltd.

Drug Package Details

Strength500 mcg + 10 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack50
Price per pack250.00
Cost per pack220.00
Package unit10 tabs strip
Price per unit5.00
Cost per unit4.40
Discount0
Coupon
Remarks

Flupenthixol + Melitracen

Flupenthixol is a typical antipsychotic drug that belongs to the thioxanthene class of compounds. It exerts its therapeutic effect by blocking postsynaptic dopamine D1 and D2 receptors in the brain. Melitracen is a tricyclic antidepressant that belongs to the dibenzazepine class of compounds. It works by inhibiting the reuptake of serotonin and norepinephrine in the brain, thereby increasing their availability and restoring the balance of neurotransmitters.

 

  • Flupenthixol + Melitracen is indicated for the treatment of depression, anxiety, and related psychiatric disorders in adults.
  • It can also be used to manage psychotic symptoms such as delusions and hallucinations in patients with schizophrenia.
  • This combination drug is available as Flupentixol 0.5 mg and melitracen 10 mg tablet.
  • The dosage of Flupenthixol + Melitracen should be individualized based on the patient's age, weight, medical condition, and response to treatment.
  • The usual recommended dose is one tablet per day, preferably taken at bedtime to minimize sedative effects.
  • The maximum recommended daily dose is 2 tablets per day.
  • The tablet should be swallowed whole with water and should not be crushed, chewed, or broken.

 

The most common adverse reactions associated with Flupenthixol + Melitracen therapy are sedation, dizziness, dry mouth, constipation, and blurred vision.

 

  • Flupenthixol + Melitracen should be used with caution in patients with a history of seizures, cardiovascular disease, liver or kidney impairment, or glaucoma.
  • It should not be used in patients with a history of hypersensitivity to any of the components of the drug or other tricyclic antidepressants.
  • Patients should be closely monitored for signs of suicidal ideation or behavior, especially during the first few weeks of treatment or after a change in dosage.
  • Flupenthixol + Melitracen may cause sedation or impair mental and physical abilities. Patients should be advised to avoid driving or operating heavy machinery until they know how the drug affects them.
  • Patients should not abruptly discontinue Flupenthixol + Melitracen therapy as it may lead to withdrawal symptoms such as nausea, vomiting, insomnia, and anxiety.
  • Flupenthixol + Melitracen should not be used during pregnancy or lactation unless clearly necessary, as it may have adverse effects on the developing fetus or infant.

 

Contraindication

  • Flupenthixol + Melitracen is contraindicated in patients with a known hypersensitivity to any of the components of the drug or other tricyclic antidepressants such as-
  • It should not be used concomitantly with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAO.

 

It should not be used in patients with a history of severe cardiovascular disease, glaucoma, or severe liver or kidney impairment.